The disclosed methods and compositions for reducing cardiovascular risk
factors in mammals generally includes using genistein to modulate various
inflammatory and cardiovascular risk markers including: homocysteine,
C-reactive protein, fibrinogen, sex hormone-binding globulin, fasting
glucose, insulin, insulin resistance, and osteoprotegerin.